According to the news report from a London based business information company, visiongain, it is predicated that the world anti-bacterial drugs revenues will reach up to $43.81bn in 2016. Between the period of 2010 and 2022, the global market will expand with a CAGR of 2.2%.
The company Visiongain forecasts that cephalosporins sector will be the largest one in the market throughout the forecast period, with revenues growing to $11.67bn by 2016. Carbapenems will be the fastest growing class of antibacterial drug with estimated revenues with a CAGR of 3% between 2010 and 2022. This growth will get a drive after the increased uptake in place of other drug classes and when will be the class’s low susceptibility to bacterial resistance.
According to the visiongain pharmaceutical industry analyst, he said that the market will rely on strong uptake of new drugs, such as Ortho-McNeil/Shionogi’s Doribax, to bring growth to 2022. But, however, newer drugs will find it increasingly difficult to reach the blockbuster status as given by the high level of generic competition expected in the market this decade.”
The above study predicts the future of the leading five classes of antibacterial drug, as well as the top 20 individual drugs, showing revenue forecasts to 2022. In 2010, only two blockbusters existed in the antibacterial drugs market – Levaquin and Zyvox – and both products are expected to have revenues below $1bn by 2017.
The leading national markets are also analysed and discussed in the report, with market forecasts provided. In 2010, China was the world’s second largest market for antibacterial drugs. Antibiotics apparently accounted for 70% of all prescriptions there in 2008. Despite of the rules introduce in 2011 to limit antibiotic drug prescription, the market will continue to grow more rapidly than those of other leading countries this decade, as predicated.
Due to bacterial resistance to antibiotics there has been an urgent medical needs exist in the antibacterial drugs industry and market. In developed and developing countries, the Nosocomial infections are a major burden on healthcare budgets. Thus, with a weak R&D pipeline in particularly against Gram-negative infections the expansion of the antibacterial drugs market will slow over in the coming 10 years.